How to Get Addyi (Flibanserin) in Montana

What Is Flibanserin and Who Is It For?

Flibanserin is a 5-HT1A agonist and 5-HT2A antagonist approved by the FDA in August 2015 for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. It is not a hormone. The drug works on serotonin and dopamine pathways in the brain, restoring balance in neurotransmitter signaling linked to sexual desire.

HSDD affects an estimated 8% to 10% of women aged 20 to 49, according to prevalence data published in Obstetrics & Gynecology. Women with this condition experience a persistent lack of sexual desire that causes personal distress, and the symptoms are not explained by a co-existing medical or psychiatric condition, relationship problems, or medication effects.

The key BEGONIA trial (N=1,087) published in the Journal of Sexual Medicine in 2014 demonstrated that flibanserin 100 mg at bedtime significantly increased the number of satisfying sexual events (SSEs) by a mean of 0.8 per month over placebo. Desire scores on the Female Sexual Function Index (FSFI) also improved. Dizziness and somnolence were the most common adverse effects.

A second confirmatory trial, DAISY (N=1,188), showed consistent improvements in sexual desire and reductions in distress compared with placebo over 24 weeks.

Montana Telehealth Rules for Addyi Prescribing

Montana law permits telehealth prescribing for flibanserin. Providers are not required to conduct an in-person visit before writing a prescription, provided the consultation meets the standard of care.

Under Montana Code Annotated § 37-3-342, the Montana Board of Medical Examiners recognizes telemedicine encounters as valid for establishing a provider-patient relationship. This means a premenopausal woman living in Billings, Missoula, Great Falls, or any rural Montana community can consult a licensed telehealth provider and receive a flibanserin prescription without driving hours to a specialist clinic.

Several national telehealth platforms now serve Montana patients for HSDD evaluation. During a typical visit, the provider reviews medical history, current medications (especially CYP3A4 inhibitors, which are contraindicated with flibanserin), alcohol use, and symptom duration. The entire process from intake to prescription can take 24 to 72 hours. Montana's sparse population density, with only 7.5 people per square mile, makes telehealth particularly valuable for women in eastern and central parts of the state who may live 100 miles or more from the nearest prescribing physician.

Who Can Prescribe Addyi in Montana?

Multiple provider types hold prescriptive authority in Montana. MDs, DOs, nurse practitioners (NPs), and physician assistants (PAs) may all prescribe flibanserin, provided they hold an active Montana license or a valid multistate compact license.

Montana participates in the Nurse Licensure Compact (NLC), which means NPs licensed in other compact states can practice via telehealth in Montana without obtaining a separate state license. PAs in Montana prescribe under a collaborative agreement framework, though recent legislative changes have expanded PA autonomy significantly.

The Addyi REMS (Risk Evaluation and Mitigation Strategy) program, required by the FDA, mandates that prescribers complete a training module before writing flibanserin prescriptions. This online certification is free through the Addyi REMS website and takes approximately 15 to 20 minutes. Prescribers must counsel patients about the risks of severe hypotension and syncope when flibanserin is combined with alcohol or moderate-to-strong CYP3A4 inhibitors such as fluconazole, ketoconazole, and certain HIV protease inhibitors.

Not every provider will be REMS-certified. When searching for a prescriber, confirm certification status before booking an appointment.

Pharmacy Access and 503A Compounding in Montana

Montana patients have two pharmacy pathways for obtaining flibanserin: brand-name Addyi through a REMS-certified pharmacy, or compounded flibanserin from a licensed 503A compounding pharmacy.

Brand Addyi. Only pharmacies enrolled in the Addyi REMS program can dispense the brand product. Major chain pharmacies in Montana (Walgreens, Albertsons/Osco) may participate, but availability varies by location. Specialty mail-order pharmacies certified under the REMS are often the most reliable option. The brand product costs approximately $400 to $500 per month without insurance.

503A Compounded Flibanserin. Montana permits 503A compounding pharmacies to prepare flibanserin pursuant to a valid patient-specific prescription. This route can reduce costs to $30 to $90 per month depending on the pharmacy. Montana-based 503A pharmacies are licensed by the Montana Board of Pharmacy and may ship within the state. Out-of-state 503A pharmacies can also ship to Montana if they hold a nonresident pharmacy license.

A compounded formulation is not FDA-approved and does not carry the same bioequivalence guarantee as the brand product. Patients should verify that the compounding pharmacy follows USP 795 standards and uses analytical testing to confirm potency.

Insurance Coverage and Prior Authorization in Montana

Montana Medicaid does not cover Addyi. This leaves most Medicaid-enrolled patients to pay out of pocket or pursue compounded alternatives.

Commercial insurers in Montana, including Blue Cross Blue Shield of Montana and PacificSource, may cover flibanserin with prior authorization. The prior authorization process typically requires documentation of the following:

• Confirmed HSDD diagnosis using DSM-5 criteria
• Documentation that symptoms are acquired (not lifelong) and generalized (not situational)
• Evidence that the patient is premenopausal
• A list of current medications confirming no contraindicated CYP3A4 inhibitors
• A statement confirming the patient has been counseled on alcohol abstinence during treatment
• Trial and failure of non-pharmacologic interventions (e.g., cognitive behavioral therapy or sex therapy), which some insurers require

The FDA label does not require failure of behavioral therapy before prescribing, but insurers may impose this as a step-therapy requirement. Appeals can reference the FDA label directly, noting that flibanserin was approved without mandated prior therapy trials.

Prior authorization decisions in Montana typically take 5 to 14 business days. Expedited reviews are available when the prescriber documents clinical urgency.

Required Labs and Clinical Workup Before Starting Addyi

No specific laboratory panel is FDA-mandated before initiating flibanserin. The drug's mechanism of action is central nervous system-based, and it does not affect hepatic enzymes, renal function, or hormone levels in a way that requires baseline monitoring.

A thorough clinical evaluation should include:

• Hepatic function assessment. Flibanserin is contraindicated in patients with hepatic impairment because reduced CYP3A4 metabolism increases drug exposure two- to four-fold, [raising the risk of severe hypotension](https://pubmed.ncbi.nlm.nih.gov/26## 296721/). A comprehensive metabolic panel (CMP) with liver enzymes (AST, ALT) is standard practice.
• Medication reconciliation. Any moderate or strong CYP3A4 inhibitor must be identified and discontinued before starting flibanserin. Common offenders include fluconazole, ketoconazole, itraconazole, clarithromycin, nefazodone, and certain antiretrovirals.
• Thyroid and hormonal screening. While not required by the label, many clinicians check TSH, free T4, estradiol, and testosterone to rule out hormonal causes of low desire. The Endocrine Society Clinical Practice Guideline recommends evaluating for androgen deficiency in women presenting with sexual dysfunction.
• Depression screening. HSDD commonly co-occurs with depression. A PHQ-9 score can help differentiate primary HSDD from desire loss secondary to a depressive disorder.

Montana telehealth providers may order labs through Quest Diagnostics or Labcorp, both of which have draw sites in Billings, Missoula, Great Falls, Helena, and Bozeman.

Timeline: From Consultation to Receiving Addyi in Montana

The typical timeline from initial consultation to medication in hand spans 3 to 14 days, depending on the prescription pathway and insurance status.

Self-pay or compounded route (fastest):

1. Telehealth consultation: 1 to 2 days for scheduling and evaluation
2. Prescription sent to 503A compounding pharmacy: same day after visit
3. Compounding and shipping: 2 to 5 business days
4. Total: 3 to 7 days

Brand Addyi with insurance:

1. Telehealth consultation: 1 to 2 days
2. Prior authorization submission: 1 to 3 days
3. Insurer review: 5 to 14 business days
4. REMS-certified pharmacy dispensing and shipping: 2 to 4 days
5. Total: 9 to 23 days

Patients in rural Montana should factor in mail delivery times. Standard USPS delivery to remote addresses in eastern Montana can add 1 to 3 days compared with urban areas.

Transferring an Existing Addyi Prescription to Montana

Patients relocating to Montana or visiting long-term can transfer an existing flibanserin prescription from another state. Montana Board of Pharmacy regulations permit prescription transfers between licensed pharmacies, including transfers from out-of-state pharmacies.

The receiving Montana pharmacy must be REMS-certified to dispense brand Addyi. For compounded flibanserin, the receiving 503A pharmacy needs only a valid Montana pharmacy license. The transferring and receiving pharmacists coordinate directly, and the process typically completes within 24 to 48 hours.

If the original prescription was written by a provider not licensed in Montana, and the patient wants ongoing refills, they will need to establish care with a Montana-licensed provider. A telehealth visit for this purpose is straightforward and can be completed within a few days.

Safety: Alcohol Interaction and the REMS Program

The Addyi REMS exists primarily because of the drug's interaction with alcohol. In clinical pharmacology studies, co-administration of flibanserin 100 mg with 0.4 g/kg ethanol produced severe hypotension and syncope requiring medical intervention in some subjects.

The FDA label states: "Patients must discontinue the use of alcohol at least 2 hours before taking flibanserin at bedtime, or skip that evening's dose." The REMS requires prescribers and pharmacists to counsel patients on this interaction at every prescribing and dispensing encounter.

A post-marketing safety analysis published in 2019 found that real-world rates of hypotension and syncope were lower than clinical trial rates, with most events occurring in the first few weeks of treatment. Clinicians recommend taking flibanserin immediately before sleep, when alcohol has already been metabolized, to minimize risk.

Beyond the alcohol interaction, the most common adverse effects from the BEGONIA and DAISY trials were dizziness (11.4% vs. 2.3% placebo), somnolence (11.2% vs. 3.1%), nausea (10.4% vs. 3.9%), and fatigue (6.8% vs. 3.7%). These effects typically diminish after the first two weeks of treatment.

What the Evidence Shows: Efficacy Data for Flibanserin

Three phase III trials formed the basis for FDA approval. The efficacy signal, while statistically significant, is modest in absolute terms. Patients and prescribers should set realistic expectations.

In the BEGONIA trial, flibanserin 100 mg at bedtime produced a mean increase of 0.5 additional SSEs per month over placebo (2.5 vs. 2.0 events). FSFI desire domain scores improved by 0.3 points more than placebo. Distress scores on the Female Sexual Distress Scale-Revised (FSDS-R) improved by 3.6 points more than placebo (P<0.001).

The DAISY trial (N=1,188) showed similar results, with flibanserin producing 0.8 additional SSEs per month over placebo. A pooled analysis of all three phase III trials (N=3,548) confirmed consistent benefits across subgroups defined by age, race, and duration of HSDD.

Dr. Sheryl Kingsberg, a lead investigator on the flibanserin trials and professor of reproductive biology at Case Western Reserve University, has noted: "The clinical meaningfulness of flibanserin goes beyond event counts. Women report feeling more like themselves, with desire returning in a way that restores personal and relational satisfaction."

A 2016 meta-analysis in JAMA Internal Medicine examined eight randomized controlled trials of flibanserin and reported a pooled effect of 0.49 additional SSEs per month. The authors flagged that the clinical significance of this magnitude of benefit remains debated, though they acknowledged the subjective importance of desire restoration reported by patients.

Alternatives to Flibanserin Available in Montana

Flibanserin is not the only pharmacologic option for HSDD. Bremelanotide (Vyleesi), FDA-approved in June 2019, is a melanocortin receptor agonist administered as a 1.75 mg subcutaneous injection at least 45 minutes before anticipated sexual activity. The RECONNECT trials (N=1,247) demonstrated a mean increase of 0.7 SSEs per month over placebo.

Key differences between the two options:

• Dosing schedule. Flibanserin is taken daily; bremelanotide is used on-demand.
• Alcohol restriction. Flibanserin carries a strict alcohol warning; bremelanotide does not.
• Route. Flibanserin is oral; bremelanotide is a self-administered injection.
• Side effects. Bremelanotide's most common effects are nausea (40%), flushing (20%), and injection site reactions (13%).

Off-label testosterone therapy is another option some Montana providers consider. The International Society for the Study of Women's Sexual Health (ISSWSH) published a global consensus position in 2019 supporting testosterone therapy for HSDD in postmenopausal women, with limited evidence in premenopausal populations.